Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION
Rebecca B. Price, Dan V. Iosifescu, James W. Murrough, et al.
Depression and Anxiety (2014) Vol. 31, Iss. 4, pp. 335-343
Open Access | Times Cited: 317

Showing 1-25 of 317 citing articles:

Mechanisms of ketamine action as an antidepressant
Panos Zanos, Todd D. Gould
Molecular Psychiatry (2018) Vol. 23, Iss. 4, pp. 801-811
Open Access | Times Cited: 895
Suicide and suicide risk
Gustavo Turecki, David A. Brent, David Gunnell, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 776
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson, Elizabeth D. Ballard, Michael H. Bloch, et al.
American Journal of Psychiatry (2017) Vol. 175, Iss. 2, pp. 150-158
Open Access | Times Cited: 577
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression
D. Jeffrey Newport, Linda L. Carpenter, William M. McDonald, et al.
American Journal of Psychiatry (2015) Vol. 172, Iss. 10, pp. 950-966
Open Access | Times Cited: 543
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Chun Yang, Yukihiko Shirayama, Ji‐chun Zhang, et al.
Translational Psychiatry (2015) Vol. 5, Iss. 9, pp. e632-e632
Open Access | Times Cited: 532
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Todd M. Hillhouse, Joseph H. Porter
Experimental and Clinical Psychopharmacology (2015) Vol. 23, Iss. 1, pp. 1-21
Open Access | Times Cited: 526
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Rebecca B. Price, Ronald S. Duman
Molecular Psychiatry (2019) Vol. 25, Iss. 3, pp. 530-543
Open Access | Times Cited: 480
Targeting glutamate signalling in depression: progress and prospects
James W. Murrough, Chadi G. Abdallah, Sanjay J. Mathew
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 7, pp. 472-486
Closed Access | Times Cited: 412
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Michael F. Grunebaum, Hanga Galfalvy, Tse‐Hwei Choo, et al.
American Journal of Psychiatry (2017) Vol. 175, Iss. 4, pp. 327-335
Open Access | Times Cited: 367
Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics
Chadi G. Abdallah, Gerard Sanacora, Ronald S. Duman, et al.
Annual Review of Medicine (2014) Vol. 66, Iss. 1, pp. 509-523
Open Access | Times Cited: 366
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
J. John Mann, Christina A. Michel, Randy P. Auerbach
American Journal of Psychiatry (2021) Vol. 178, Iss. 7, pp. 611-624
Open Access | Times Cited: 352
Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
Taishiro Kishimoto, Jatinder Mohan Chawla, Katsuhiko Hagi, et al.
Psychological Medicine (2016) Vol. 46, Iss. 7, pp. 1459-1472
Open Access | Times Cited: 321
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
James W. Murrough, Laili Soleimani, Kaitlin E. DeWilde, et al.
Psychological Medicine (2015) Vol. 45, Iss. 16, pp. 3571-3580
Closed Access | Times Cited: 276
Suicide risk assessment and intervention in people with mental illness
Shay‐Lee Bolton, David Gunnell, Gustavo Turecki
BMJ (2015) Vol. 351, Iss. nov09 1, pp. h4978-h4978
Open Access | Times Cited: 269
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
Elizabeth D. Ballard, Dawn F. Ionescu, Jennifer L. Vande Voort, et al.
Journal of Psychiatric Research (2014) Vol. 58, pp. 161-166
Open Access | Times Cited: 256
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Caoimhe M. Coyle, Keith R. Laws
Human Psychopharmacology Clinical and Experimental (2015) Vol. 30, Iss. 3, pp. 152-163
Open Access | Times Cited: 250
Ketamine use in current clinical practice
Mei Gao, Damoon Rejaei, Hong Liu
Acta Pharmacologica Sinica (2016) Vol. 37, Iss. 7, pp. 865-872
Open Access | Times Cited: 248
The molecular bases of the suicidal brain
Gustavo Turecki
Nature reviews. Neuroscience (2014) Vol. 15, Iss. 12, pp. 802-816
Open Access | Times Cited: 246
Mechanistic Target of Rapamycin–Independent Antidepressant Effects of ( R )-Ketamine in a Social Defeat Stress Model
Chun Yang, Qian Ren, Youge Qu, et al.
Biological Psychiatry (2017) Vol. 83, Iss. 1, pp. 18-28
Open Access | Times Cited: 222
Ketamine abuse potential and use disorder
Yu Liu, Deyong Lin, Boliang Wu, et al.
Brain Research Bulletin (2016) Vol. 126, pp. 68-73
Open Access | Times Cited: 213
Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder
Hannah Zuckerman, Zihang Pan, Caroline Park, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 209
Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model
Chun Yang, Youge Qu, Yūkō Fujita, et al.
Translational Psychiatry (2017) Vol. 7, Iss. 12
Open Access | Times Cited: 196
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review
Nicolas D. Iadarola, Mark J. Niciu, Erica M. Richards, et al.
Therapeutic Advances in Chronic Disease (2015) Vol. 6, Iss. 3, pp. 97-114
Open Access | Times Cited: 189
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Eduardo Ekman Schenberg
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 188
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio, Argel Aguilar‐Valles, Katrin H. Preller, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 5, pp. 891-900
Open Access | Times Cited: 186
Page 1 - Next Page

Scroll to top